Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores
Arun J. Sanyal, Julie Foucquier, Zobair M. Younossi, et al.
Journal of Hepatology (2022) Vol. 78, Iss. 2, pp. 247-259
Open Access | Times Cited: 107

Showing 1-25 of 107 citing articles:

Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 169
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
Huapeng Lin, Hye Won Lee, Terry Cheuk‐Fung Yip, et al.
JAMA (2024) Vol. 331, Iss. 15, pp. 1287-1287
Open Access | Times Cited: 55
Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitis
Arun J. Sanyal, Sudha S. Shankar, Katherine P. Yates, et al.
Nature Medicine (2023) Vol. 29, Iss. 10, pp. 2656-2664
Open Access | Times Cited: 51
Non-invasive testing and risk-stratification in patients with MASLD
Mirko Zoncapè, Antonio Liguori, Emmanuel Tsochatzis
European Journal of Internal Medicine (2024) Vol. 122, pp. 11-19
Closed Access | Times Cited: 30
New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Monica A. Tincopa, Quentin M. Anstee, Rohit Loomba
Cell Metabolism (2024) Vol. 36, Iss. 5, pp. 912-926
Closed Access | Times Cited: 30
Golgi protein 73: charting new territories in diagnosing significant fibrosis in MASLD: a prospective cross-sectional study
Shan Hong, Ziyu Liu, Ping Li, et al.
Frontiers in Endocrinology (2025) Vol. 15
Open Access | Times Cited: 1
Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes
Grazia Pennisi, Marco Enea, Vincenzo Falco, et al.
Hepatology (2023) Vol. 78, Iss. 1, pp. 195-211
Open Access | Times Cited: 32
Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms
Μargarita Papatheodoridi, Victor de Lédinghen, Monica Lupșor‐Platon, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 10
Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease
Nabil Noureddin, Nedret Copur‐Dahi, Rohit Loomba
Alimentary Pharmacology & Therapeutics (2024) Vol. 59, Iss. S1
Closed Access | Times Cited: 9
Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA
Alexander H. Yang, Monica A. Tincopa, Federica Tavaglione, et al.
Gut (2024) Vol. 73, Iss. 12, pp. 2045-2053
Open Access | Times Cited: 9
Alcohol-associated liver cancer
Yaojie Fu, Luca Maccioni, Xin Wei Wang, et al.
Hepatology (2024) Vol. 80, Iss. 6, pp. 1462-1479
Closed Access | Times Cited: 8
Guideline for the Prevention and Treatment of Metabolic Dysfunction-associated Fatty Liver Disease (Version 2024)
Jian‐Gao Fan, Xiaoyuan Xu, Rui-Xu Yang, et al.
Journal of Clinical and Translational Hepatology (2024) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 7
Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: independent validation of the Agile 3+ and 4 scores
Mazen Noureddin, Edward Mena, Raj Vuppalanchi, et al.
Hepatology Communications (2023) Vol. 7, Iss. 5
Open Access | Times Cited: 21
Serum PRO‐C3 is useful for risk prediction and fibrosis assessment in MAFLD with chronic kidney disease in an Asian cohort
Liang‐Jie Tang, Dan‐Qin Sun, Sherlot Juan Song, et al.
Liver International (2024) Vol. 44, Iss. 5, pp. 1129-1141
Closed Access | Times Cited: 5
KASL Clinical Practice Guidelines for Noninvasive Tests to Assess Liver Fibrosis in Chronic Liver Disease
Mi Na Kim, Ji Won Han, Jihyun An, et al.
Clinical and Molecular Hepatology (2024) Vol. 30, Iss. Suppl, pp. S5-S105
Open Access | Times Cited: 5
Guided-VCTE: An Enhanced FibroScan Examination With Improved Guidance and Applicability
Cécile Bastard, Stéphane Audière, Julie Foucquier, et al.
Ultrasound in Medicine & Biology (2025)
Open Access
Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease
Terry Cheuk‐Fung Yip, Hye Won Lee, Huapeng Lin, et al.
Journal of Hepatology (2025)
Open Access
How to Identify Advanced Fibrosis in Adult Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Using Ultrasound Elastography—A Review of the Literature and Proposed Multistep Approach
Mădălina-Gabriela Țâru, Lidia Neamți, Vlad Țâru, et al.
Diagnostics (2023) Vol. 13, Iss. 4, pp. 788-788
Open Access | Times Cited: 14
Agile 3+ and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver‐related events in nonalcoholic fatty liver disease
Kouichi Miura, Hideki Hayashi, Yoshihiro Kamada, et al.
Hepatology Research (2023) Vol. 53, Iss. 10, pp. 978-988
Closed Access | Times Cited: 14
Poor Performance of Non-invasive Tests for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: A Multicentric Asian Study
Umang Arora, Ritik M. Goyal, Kevin Teh, et al.
Digestive Diseases and Sciences (2023) Vol. 68, Iss. 12, pp. 4485-4498
Closed Access | Times Cited: 14
Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis
Andrea Dalbeni, Rosa Lombardi, M. K. Costa Luís Henrique, et al.
Hepatology (2023) Vol. 79, Iss. 5, pp. 1107-1116
Closed Access | Times Cited: 13
Interactions between Metabolic Syndrome, MASLD, and Arterial Stiffening: A Single-Center Cross-Sectional Study
Adelaida Solomon, Mihai Octavian Negrea, Călin Remus Cipăian, et al.
Healthcare (2023) Vol. 11, Iss. 19, pp. 2696-2696
Open Access | Times Cited: 12
A roadmap for clinical trials in MASH-related compensated cirrhosis
Juan M. Pericàs, Quentin M. Anstee, Salvador Augustín, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 11, pp. 809-823
Closed Access | Times Cited: 4
Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation
Sin Man Lam, Zehua Wang, Jin‐Wen Song, et al.
Cell Metabolism (2024)
Closed Access | Times Cited: 4
Liver Elastography for Liver Fibrosis Stratification: A Comparison of Three Techniques in a Biopsy-Controlled MASLD Cohort
Antonio Liguori, Giorgio Esposto, Maria Elena Ainora, et al.
Biomedicines (2025) Vol. 13, Iss. 1, pp. 138-138
Open Access
Page 1 - Next Page

Scroll to top